Published in J Cell Mol Med on November 20, 2007
Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J Cell Mol Med (2008) 0.90
Neurovascular changes measured by time-of-flight MR angiography in cholesterol-fed rabbits with cortical amyloid beta-peptide accumulation. J Magn Reson Imaging (2010) 0.80
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci (2007) 5.72
Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol (2006) 2.33
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J Cell Mol Med (2005) 1.62
Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol (2007) 1.59
Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers. Biochim Biophys Acta (2007) 1.35
CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn (2005) 1.25
Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med (2008) 1.16
Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med (2007) 1.13
MitoQ--a mitochondria-targeted antioxidant. IDrugs (2007) 1.06
The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J (2007) 1.05
Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. J Cell Mol Med (2006) 1.03
Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets (2007) 0.99
Presenilin-mediated signal transduction. Physiol Behav (2007) 0.96
Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother (2007) 0.90
Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med (2007) 0.88
Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain. Curr Neurovasc Res (2007) 0.85
A new framework for the diagnosis of Alzheimer's disease. Lancet Neurol (2007) 0.84
Occludin is overexpressed in Alzheimer's disease and vascular dementia. J Cell Mol Med (2007) 0.84
Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease. J Cell Mol Med (2006) 0.81
Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs (2007) 0.80
Platelet-derived growth factor receptor-β-positive telocytes in skeletal muscle interstitium. J Cell Mol Med (2012) 1.20
The presenilin 1 deltaE9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations. J Biol Chem (2002) 0.99
Neuroregeneration in neurodegenerative disorders. BMC Neurol (2011) 0.98
Presenilin-mediated signal transduction. Physiol Behav (2007) 0.96
Intracranial cysts: an imagery diagnostic challenge. ScientificWorldJournal (2013) 0.92
Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxid Med Cell Longev (2013) 0.87
Occludin is overexpressed in Alzheimer's disease and vascular dementia. J Cell Mol Med (2007) 0.84
Is there a causal link between inflammation and dementia? Biomed Res Int (2013) 0.84
Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains. J Cell Mol Med (2010) 0.82
Microemboli detection in patients with carotid artery stenting--a potential marker for future cognitive impairment? J Neurol Sci (2013) 0.81
Placebo effects in neurological diseases. J Med Life (2010) 0.81
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci (2010) 0.79
A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. J Neurol Sci (2007) 0.78
Neurobiology of vascular dementia. J Aging Res (2011) 0.77
Functional and molecular characterization of the effect of amyloid-β42 on an in vitro epithelial barrier model. J Alzheimers Dis (2014) 0.77
Caspase cleaved presenilin-1 is part of active gamma-secretase complexes. J Neurochem (2006) 0.77
Claudin expression profile separates Alzheimer's disease cases from normal aging and from vascular dementia cases. J Neurol Sci (2012) 0.76
Label free sensing platform for amyloid fibrils effect on living cells. Biosens Bioelectron (2013) 0.76
A hypertensive patient with multiple intracerebral hemorrhages due to brain metastases. J Med Life (2010) 0.75